

ALKALOIDS FROM *SARCOCAPNOS ENNEAPHYLLA*

EMILIA TOJO, DOMINGO DOMINGUEZ and LUIS CASTEDO

Departamento de Química Orgánica de la Facultad de Química y Sección de Alcaloides del CSIC, Santiago de Compostela, Spain

(Received 15 June 1990)

Key Word Index—*Sarcocapnos enneaphylla*; Fumariaceae; alkaloid content; isoquinoline alkaloids; cularines.

Abstract—Chemical investigation of *Sarcocapnos enneaphylla* resulted in the isolation of 35 alkaloids, 27 of which were identified as known isoquinoline alkaloids. The remainder were found to be a new aporphinoid, *N*-methylsecoglaucine, a new morphinandienone, (+)-*O*-methylpallidine *N*-oxide and six new cularines, (+)-enneaphylline, (+)-sarcophylline, (+)-4-hydroxysarcocapnine, aristoyagonine, secosarcocapnine and norsecosarcocapnine. Their structures were elucidated by spectroscopic and chemical methods.

INTRODUCTION

The genus *Sarcocapnos* (Fumariaceae) has been shown to be a rich source of isoquinoline alkaloids, most of them with a cularine skeleton [1]. In continuance of our chemical research on the alkaloids of Spanish Fumariaceae, an intensive study of *S. enneaphylla* was carried out. The plant is a caespitose, perennial herb typical of the Meridional Iberic System mountains [2]. Previous work from our laboratory of this plant [3] resulted in the isolation of the first natural cancentrine-type [4] cularines, (+)-sarcocapnine (4) [5], oxosarcocapnine (7) [5], oxosarcophylline (8) [6], oxosarcocapnidine (9) [7] and yagonine (11) [6], together with the new classical cularines (+)-celtine (2) [8], (+)-celtisine (3) [8] and oxocompostelline (6) [9], the new example of a ribasine alkaloid, (+)-ribasidine (17) [10] and 11 known alkaloids, cularicine, cularidine [11], glaucine, *O*-methylatherolone [12], dihydrosanguinarine, norsanguinarine, oxisanguinarine, sanguinarine, chelidonine, chelamine [13] and protopine [14]. A re-examination of the components of *S. enneaphylla* has now led us to the isolation of another six new cancentrine-type cularines, a new aporphinoid and a new morphinandienone.

RESULTS AND DISCUSSION

Extraction and separation of alkaloids were performed by the usual procedures as described in the Experimental. Thirty-five different isoquinolines were isolated, 27 of them being identified as the known alkaloids (+)-celtine (2) [8], (+)-celtisine (3) [8], (+)-sarcocapnine (4) [5], (+)-sarcocapnidine (7), (+)-cularine, (+)-cularicine, (+)-cularidine [11], oxocompostelline (6) [9], oxosarcocapnine (7) [5], (+)-oxosarcophylline (8) [6], oxosarcocapnidine (9) [7], yagonine (11) [6], secocularine [15], (+)-glaucine, (+)-isocoridine, *O*-methylatherolone, corunnine, pontevedrine, dehydroglaucine [12], (+)-chelidonine, (+)-chelamine, (+)-8-hydroxymethyldihydrosanguinarine [13], protopine [14], (–)-scoulerine [16], (+)-ribasine [17], (+)-ribasidine (17) [10] and (+)-*O*-methylpallidine [18, 19]. Their structures were


established spectroscopically and by direct comparison with authentic samples.

The remaining eight compounds were identified as six new cularines, a new aporphinoid and a new morphinandienone. They were named as (+)-enneaphylline (1), (+)-sarcophylline (5), (+)-4-hydroxysarcocapnine (10), aristoyagonine (12), secosarcocapnine (13), norsecosarcocapnine (14), *N*-methylsecoglaucine (15) and (+)-*O*-methylpallidine *N*-oxide (16). Their structures were elucidated by spectroscopic analysis and confirmed by chemical transformations and partial or total synthesis.

(+)-Enneaphylline (1), C₁₉H₂₁NO₄, was obtained as prisms, mp 205–207° (EtOH). The bathochromic shift of its UV spectrum in basic media together with the broad IR signal at 3440 cm^{–1} revealed its phenolic nature. The ¹H NMR suggested a cularine-type structure. The mass spectrum with its base peak at *m/z* 327 [M]⁺, showed the hydroxyl group to be located at C-3' [1], which was also supported by NOEDS experiments (Experimental). Structure 1 for enneaphylline was finally confirmed by comparison with the synthetic product obtained from crassifoline by phenolic oxidative coupling [20, 21].

(+)-Sarcophylline (5), C₁₉H₂₁NO₄, was isolated as an amorphous powder. The bathochromic shift of its UV spectrum in basic media together with the broad IR signal at 3400 cm^{–1} revealed its phenolic nature. The isocularine skeleton was deduced from its ¹H NMR spectrum which exhibited two methoxyl singlets and two aromatic AB quartets; all assignments were supported by NOEDS experiments (Experimental). Confirmation of structure 5 for sarcophylline was obtained by its conversion into sarcocapnine (4) after methylation with diazomethane [20].

(+)-4-Hydroxysarcocapnine (10), C₂₀H₂₃NO₅, was shown to be the first known isocularine alkaloid bearing a hydroxyl group at C-4. The IR spectrum in CCl₄ exhibited a broad band at 3511 cm^{–1}, which did not change upon dilution and was therefore attributed to an intramolecularly hydrogen bonded hydroxyl. Its ¹H NMR was very significant, showing two doublets of doublets for H-1 (δ 4.17, $J_{1-\alpha\alpha} = 2.9$, $J_{1-\alpha\beta} = 11.3$ Hz) and H-4 (δ 4.58, $J_{4-3\alpha} = 2.3$, $J_{4-3\beta} = 3.9$ Hz). All assignments



were based on decoupling and NOES experiments (Experimental). Configuration at C-4 was confirmed by total synthesis of both epimers by means of the oxidation of a suitable precursor at the benzylic position [22, 23].


Aristoyagonine (12), $C_{19}H_{17}NO_5$, was obtained as yellow needles. Its UV spectrum showed absorptions at 220, 230, 250, 296, 330 (sh) and 410 nm and the IR spectrum displayed bands at 1700 and 1680 cm^{-1} . ^1H NMR and NOES experiments suggested an aristoisolarine-type structure. This assignment was also supported by the ^{13}C NMR and mass spectra (Experimental). Structure 12 for aristoyagonine was finally confirmed by comparison with synthetic material obtained from yagonine (11) [6, 23].

The secocularine nature of secosarcocapnine (13) and norsecosarcocapnine (14) was deduced on the bases of the ^1H NMR spectra. Characteristic signals in the aliphatic region suggested the presence of a $\text{CH}_2\text{CH}_2\text{NMe}_2$ side chain in compound 13 and $\text{CH}_2\text{CH}_2\text{NHMe}$ in compound 14. NOES experiments confirmed all assignments. This interpretation was supported by the presence of base peaks in the mass spectra at m/z 58 ($[\text{CH}_2=\text{NMe}_2]^+$) and 44 ($[\text{CH}_2=\text{NHMe}]^+$), respectively. The structure of secosarcocapnine (13) was confirmed by

direct comparison with the synthetic product obtained by Hoffmann degradation of sarcocapnine methiodide [24]. Structure 14 for norsecosarcocapnine was confirmed by partial synthesis from the parent sarcocapnine (4) by means of Cope elimination of its *N*-oxide [25] and by transformation into secosarcocapnine (13) via *N*-methylation.

N-Methylsecoglaucine* (15), $C_{22}H_{27}NO_4$, was isolated as an amorphous powder. Its UV spectrum showed a highly conjugated system with maxima at 269, 285 (sh), 322, 349 and 367 nm. The ^1H NMR spectrum displayed five aromatic protons, three as singlets and two as an AB system. Characteristic signals in the aliphatic region suggested the presence of a $\text{CH}_2\text{CH}_2\text{NMe}_2$ side chain. This was supported by the base peak observed in the mass spectrum at m/z 58 ($[\text{CH}_2=\text{NMe}_2]^+$). Further proof for structure 15 came from direct comparison (TLC R_f , IR, ^1H NMR and mass spectrum with synthetic material obtained by Hoffmann degradation of glaucine meth-

*This alkaloid was simultaneously isolated in our Laboratories from *Platycapnos spicata*. Blanco, O., Castedo, L., Cid, M. M., Seijas, J. A. and Villaverde, M. C.



* Chemical shifts with identical superscripts are interchangeable.

iodide [26]. ^1H NMR assignments, shown around **15**, were confirmed by NOEDS experiments (Experimental).

(+)-*O*-Methylpallidine *N*-oxide (**16**), $\text{C}_{20}\text{H}_{23}\text{NO}_5$, was obtained as an amorphous substance. Its UV spectrum (240, 286 nm) and IR spectrum (1670, 1640, 1620 cm^{-1}) were reminiscent of a morphinandienone [27]. The aromatic region of the ^1H NMR spectrum exhibited four one-proton singlets at δ 6.87, 6.62, 6.52 and 6.38, as well as three singlets at δ 3.91, 3.87 and 3.82 for three methoxyl groups, a pattern very close to that of *O*-methylpallidine. In addition, the H-9 doublet centred at δ 4.32 ($J = 5.3$ Hz), and the downfield chemical shift of the *N*-methyl singlet (δ 3.40) suggested the presence of an *N*-oxide functionality. This assumption was supported by the mass spectrum which showed the $[\text{M}]^+$ at m/z 357 and other significant peaks at m/z 341 $[\text{M} - 16]^+$, 298 (40) and 284 (100). Further proof for structure **16** was obtained from ^{13}C NMR which was very close to that of *O*-methylpallidine [28], the only difference lying in the signals of groups bound to *N* (Me, C-9 and C-16) which appear on the *N*-oxide at ca 15 ppm lower field. Similar differences were

observed for the ^{13}C NMR thebaine and its *N*-oxide [29]. Structure **16** for *O*-methylpallidine *N*-oxide was finally confirmed by comparison with synthetic material obtained by treatment of (+)-*O*-methylpallidine (**16**) with *m*-chloroperbenzoic acid [30].

EXPERIMENTAL

General. Mps: uncorr. MS were recorded at 70 eV, HRMS at the Midwest Center for Mass Spectrometry (University of Nebraska, U.S.A.). Both ^1H NMR were recorded in CDCl_3 at 250 and 80 MHz with TMS as int. standard; all data are summarized on the corresponding structure. Coupling constants are in Hz. CC was carried out on Merck silica gel and Woelm N (grade IV) neutral alumina. TLC was performed on Merck GF-254 type 60 silica gel and neutral alumina plates with the following solvent systems: C_6H_6 -EtOAc-Et₂NH (7:2:1), EtOAc- CHCl_3 -EtOH (1:1:1), CH_2Cl_2 -MeOH (49:1), (19:1) and (9:1), hexane- C_6H_6 (1:1), hexane-Et₂O (1:1), (2:1) and (3:1). Alkaloids were detected by UV and after spraying with Dragendorff's reagent or I_2 vapour.

Plant material. *Sarcocapnos enneaphylla* (L.) DC. was collected in June 1982 in Cuenca, Spain. A voucher specimen is deposited in the Herbarium of the Department of Botany, Faculty of Pharmacy, University of Santiago de Compostela, Spain.

Extraction of alkaloids. Ground, air-dried whole plant (10 kg) was exhaustively extracted with MeOH. The MeOH extract was concd to small vol. and kept cold to leave a resinous ppt. The extract was filtered and concd to a viscous residue that was dissolved in 5% HCl. The acid soln was washed with Et₂O, made alkaline by addition of 20% NaOH and extracted with CH₂Cl₂. The organic extract was dried (Na₂SO₄) and evapd to give 80 g of an oily residue (Ext. A) which was chromatographed over 2 kg of silica gel using a CH₂Cl₂-MeOH stepwise gradient to afford 38 frs. Each was purified by prep. TLC or fractionally crystallized to give 35 alkaloids, which were by order of increasing polarity on TLC: dehydroglauanine (0.230 g), yagonine (11) (0.100 g), aristoyagonine (12) (0.070 g), oxosarcocapnine (7) (0.310 g), oxosarcophylline (8) (0.250 g), (+)-chelidonine (3.00 g), (+)-ribasine (0.200 g), (+)-ribasidine (17) (0.050 g), (+)-sarcophylline (5) (0.030 g), (+)-sarcocapnine (4) (10.5 g), (+)-sarcocapnidine (0.070 g), (+)-cularine (0.150 g), (+)-4-hydroxysarcocapnine (10) (0.350 g), (+)-chelamine (0.500 g), (+)-glauanine (0.300 g), (+)-isocoridine (0.150 g), (+)-enneaphylline (1) (0.050 g), *O*-methylatheroline (0.215 g), corunnine (0.060 g), (+)-*O*-methylpallidine (0.125 g), pontevedrine (0.080 g), secosarcocapnine (13) (0.165 g), secocularine (0.030 g), *N*-methylsecoglauanine (0.045 g) (15), (+)-8-hydroxymethyl-dihydrosanguinarine (0.030 g), protopine (4.00 g), (-)-scoulerine (0.020 g), norsecosarcocapnine (14) (0.055 g) and (+)-*O*-methylpallidine *N*-oxide (16) (0.030 g). The alkaline aq. extracts remaining were extracted with CH₂Cl₂ at pH 7 after successive additions of HCl and NH₄Cl. The organic extracts were dried (Na₂SO₄) and evapd to give 21 g of an oily residue (Ext. B) which was chromatographed over neutral alumina using a C₆H₆-CH₂Cl₂-MeOH stepwise gradient to afford 23 frs. TLC showed the presence of some cularines previously isolated from the plant: cularidine, cularicine [11], celtine (2) [8], celtisine (3) [8], oxocompostelline (6) [9] and oxosarcocapnidine (9) [7]. All known alkaloids were identified by comparison of their physical and spectroscopic data with those of authentic samples previously isolated in our laboratories or with those reported in the literature.

(+)-*Enneaphylline* (1). Prisms, mp 205–207° (EtOH). [α]_D +256° (EtOH; c 0.8). UV $\lambda_{\text{max}}^{\text{EtOH}}$ (log ϵ) nm: 226 (4.04), 284 (3.85); $\lambda_{\text{max}}^{\text{EtOH}-\text{NaOH}}$ (log ϵ) nm: 223 (4.33), 284 (3.66), 303 (3.71). IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3440 (OH). EIMS *m/z* (rel. int.): 327 [M]⁺ (100), 312 [M-Me]⁺ (64), 174 (39). Molecular formula C₁₉H₂₁NO₄ [M]⁺ (c: 327.1470; HRMS f: 327.1465). Significant ¹H NMR NOEDS are: MeOC-7 to H-6, 5%; H-2' to H- α , 4%; MeOC-4' to H-5', 6%.

(+)-*Celtine* (2). Mp 94–96° (EtOH). [α]_D +181° (MeOH; c 0.08). UV $\lambda_{\text{max}}^{\text{EtOH}}$ (log ϵ) nm: 216 (4.11), 228 (3.95) (sh), 282 (3.58); $\lambda_{\text{max}}^{\text{EtOH}-\text{NaOH}}$ (log ϵ) nm: 216 (4.59), 298 (3.60). IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3350, 1510, 1280. EIMS *m/z* (rel. int.): 327 [M]⁺ (45), 312 (100), 284 (9), 253 (8), 174 (10). Molecular formula C₁₉H₂₁NO₄ [M]⁺ (c: 327.1470; HRMS f: 327.1483).

(+)-*Celtisine* (3). Mp 158–160° (EtOH). [α]_D +212° (MeOH; c 0.025). UV $\lambda_{\text{max}}^{\text{MeOH}}$ (log ϵ) nm: 225 (4.10), 283 (3.85); $\lambda_{\text{max}}^{\text{EtOH}-\text{NaOH}}$ (log ϵ) nm: 225 (4.50), 294 (3.91). IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3400, 1510, 1305. EIMS *m/z* (rel. int.): 313 [M]⁺ (54), 298 (100), 296 (12), 270 (9), 161 (5). Molecular formula C₁₈H₁₉NO₄ [M]⁺ (c: 313.1314; HRMS f: 313.1328).

(+)-*Sarcocapnine* (4). Crystallized as its hydrochloride, mp 210–212° (EtOH-Et₂O). [α]_D +210° (EtOH; c 0.29). UV $\lambda_{\text{max}}^{\text{EtOH}}$ (log ϵ) nm: 232 (4.12), 283 (3.14). EIMS *m/z* (rel. int.): 341 [M]⁺ (100), 326 (58), 298 (21), 176 (85), 174 (60). Anal. calc. for

C₂₀H₂₃NO₄: C, 63.58; H, 6.36; N, 3.71. Found: C, 63.67; H, 6.63; N, 3.52.

(+)-*Sarcophylline* (5). Amorphous powder. [α]_D +200° (CHCl₃; c 1.65). UV $\lambda_{\text{max}}^{\text{EtOH}}$ (log ϵ) nm: 219 (4.01), 282 (3.86); $\lambda_{\text{max}}^{\text{EtOH}-\text{NaOH}}$ (log ϵ) nm: 222 (4.10), 285 (3.36), 293 (3.40). IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3400 (OH). EIMS *m/z* (rel. int.): 327 [M]⁺ (100), 312 (56), 294 (53), 162 (66). Molecular formula C₁₉H₂₁NO₄ [M]⁺ (c: 327.1470; HRMS f: 327.1470). Significant ¹H NMR NOEDS are: H-3' to MeOC-4', 10%; MeOC-4' to H-3', 5%.

***O*-Methylation of sarcophylline (5).** A MeOH soln of sarcophylline (5) was left overnight with excess CH₂N₂ in dry Et₂O. Air was then bubbled to eliminate excess reagent and solvent removed under red. pres. *R_f* values, ¹H NMR and MS of the resulting product were identical with those of natural sarcocapnine (4).

***Oxocompostelline* (6).** C₁₈H₁₁NO₅, yellow crystals, mp 259–260° (EtOH). UV $\lambda_{\text{max}}^{\text{EtOH}}$ (log ϵ) nm: 208 (4.67), 254 (4.41), 292 (sh), 397 (3.61); $\lambda_{\text{max}}^{\text{EtOH}-\text{HCl}}$ (log ϵ) nm: 208 (4.67), 261 (4.34), 4.10 (3.47), 4.60 (3.23). IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹: 1670. EIMS *m/z* (rel. int.): 321 [M]⁺ (72), 306 (5), 293 (5), 278 (100).

***Oxosarcocapnine* (7).** Yellow crystals, mp 200–201° (EtOH). UV $\lambda_{\text{max}}^{\text{EtOH}}$ (log ϵ) nm: 254 (4.19), 330 (3.16), 400 (3.53); $\lambda_{\text{max}}^{\text{EtOH}-\text{HCl}}$ nm: 266, 398, 462. IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3000. EIMS *m/z* (rel. int.): 337 [M]⁺ (100), 309 (12), 306 (20), 294 (62), 279 (10), 251 (12), 236 (20), 208 (7), 189 (9). Anal. calc. for C₁₉H₁₅NO₅: C, 67.41; H, 4.30; N, 3.92. Found: C, 67.66; H, 4.45; N, 4.15.

***Oxosarcophylline* (8).** Yellow needles, mp 170–171° (EtOH). UV $\lambda_{\text{max}}^{\text{EtOH}}$ (log ϵ) nm: 218 (4.48), 252 (4.27), 330 (3.54), 396 (3.61); $\lambda_{\text{max}}^{\text{EtOH}}$ (log ϵ) nm: 218 (4.48), 260 (4.24), 395 (3.53), 470 (3.25); $\lambda_{\text{max}}^{\text{EtOH}-\text{NaOH}}$ (log ϵ) nm: 218 (4.37), 280 (4.25), 310 (3.90) (sh), 510 (3.52). IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹: 1670, 3400. EIMS *m/z* (rel. int.): 323 [M]⁺ (100), 306 (34), 295 (27), 292 (31), 280 (17), 272 (17), 237 (28), 209 (17), 181 (12), 153 (28). Molecular formula C₁₈H₁₃NO₅ [M]⁺ (c: 323.0794; HRMS f: 323.0798).

***Oxosarcocapnidine* (9).** Yellow crystals, mp 231–232° (MeOH). UV $\lambda_{\text{max}}^{\text{EtOH}}$ (log ϵ) nm: 252 (4.26), 342 (3.34), 396 (3.59); $\lambda_{\text{max}}^{\text{EtOH}-\text{NaOH}}$ (log ϵ) nm: 243 (4.26), 340 (3.34), 400 (3.57); $\lambda_{\text{max}}^{\text{EtOH}-\text{HCl}}$ (log ϵ) nm: 217 (4.28), 265 (4.05), 458 (3.55). IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3400, 1670. EIMS *m/z* (rel. int.): 323 [M]⁺ (100), 308 (8), 306 (14), 295 (13), 280 (50), 265 (11), 237 (16), 209 (11). Molecular formula C₁₈H₁₃NO₅ [M]⁺ (c: 323.0790; HRMS f: 323.0807).

(+)-*4-Hydroxysarcocapnine* (10). Prisms, mp 145–146° (EtOH). [α]_D +314° (CHCl₃; c 0.11). UV $\lambda_{\text{max}}^{\text{EtOH}}$ (log ϵ) nm: 218 (4.26), 230 (4.09) (sh), 282 (3.46). IR $\nu_{\text{max}}^{\text{CCl}_4}$ cm⁻¹: 3511 (no change upon dilution). ¹³C NMR (62.83 MHz, CDCl₃): δ 151.99 (s), 151.05 (s), 148.47 (s), 143.37 (s), 140.40 (s), 133.42 (s), 128.79 (s), 125.06 (d), 124.90 (d), 120.69 (s), 111.12 (d), 107.20 (d), 66.17 (d), 61.07 (q), 58.60 (d), 57.40 (t), 56.05 (q), 55.96 (q), 43.12 (q, NMe), 37.40 (t, C- α). EIMS *m/z* (rel. int.): 357 [M]⁺ (86), 342 (49), 324 (49), 314 (26), 192 (100), 190 (43). Anal. calc. for C₂₀H₂₃NO₅: C, 67.00; H, 6.40; N, 3.90. Found: C, 67.39; H, 6.51; N, 3.90. Significant ¹H NMR NOEDS are: H-1 to H-3 α , 2%; H-1 to NMe, 6%; H-1 to H- α , 3%; H- α to H-1, 7%; H- α to H-2', 9%; H- α to NMe, 6%; H-4 to H-3 α , 4%, H-4 to H-3 β , 3%; H-4 to H-5, 9%.

***Yagonine* (11).** Red needles, mp 226–227° (EtOH). UV $\lambda_{\text{max}}^{\text{EtOH}}$ nm: 217, 254, 340, 435. IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹: 1680, 1590. ¹³C NMR (62.83 MHz, CDCl₃): δ 175.24 (s, CO), 156.96 (s, CO), 156.76 (s), 155.33 (s), 149.30 (s), 141.98 (s), 141.33 (s), 133.48 (s), 130.03 (s), 122.29 (s), 121.82 (s), 126.83 (d), 124.26 (d), 118.59 (d), 113.94 (d), 108.95 (d), 61.61 (q), 56.47 (q), 56.22 (q), 32.92 (q, NMe). EIMS *m/z* (rel. int.): 367 [M]⁺ (20), 366 (100), 338 (55), 323 (57), 308 (13), 280 (25). Molecular formula C₂₀H₁₇NO₆ [M]⁺ (C: 367.1056; HRMS f: 367.1061).

***Aristoyagonine* (12).** Yellow needles, mp 165–166° (MeOH). UV $\lambda_{\text{max}}^{\text{EtOH}}$ nm: 220, 230, 250, 296, 330 (sh), 410. IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹:

1700, 1680. EIMS m/z (rel. int.): 339 $[M]^+$ (100), 324 (30), 309 (7), 296 (10), 281 (17), 253 (12), 238 (27). Molecular formula $C_{19}H_{17}NO_5$, $[M]^+$ (c: 339.1107; HRMS f: 339.1107). ^{13}C NMR (62.83 MHz, $CDCl_3$): δ 166.13 (s, CO), 154.94 (s), 152.14 (s), 148.05 (s), 141.87 (s), 141.48 (s), 135.42 (s), 127.79 (s), 125.82 (s), 122.03 (s), 121.62 (s), 118.80 (s), 115.03 (s), 108.21 (s), 107.94 (s), 61.19 (q), 56.70 (q), 56.07 (q), 25.49 (q, NMe). Significant 1H NMR NOEDS are: H-4 to H-5, 6%; H-5 to H-4, 4%; H-5 to MeOC-6, 5%; H- α to H-2', 8%; H-2' to H- α , 6%; H- α to NMe, 6%; NMe to H- α , 2%; H-3' to MeOC-4', 7%; MeOC-4' to H-3', 3%.

Secosarcocapnine (13). Crystallized as its hydrochloride, mp 186–188° (EtOH–Et₂O). UV λ_{max}^{EtOH} (log ϵ): 206 (4.1), 219 (3.9), 246 (3.7), 312 (3.7). IR ν_{max}^{KBr} cm^{-1} : 3000–2650, 1595, 1480, 1275, 1095. EIMS m/z (rel. int.): 355 $[M]^+$ (4), 298 (1), 165 (2), 152 (2), 139 (2), 58 (100). Molecular formula $C_{21}H_{23}NO_4$, $[M]^+$ (c: 355.1784; HRMS f: 355.1795). Significant 1H NMR NOEDS are: H-3 to H-4, 5%; MeOC-6 to H-5, 5%; MeOC-9 to H-10, 6%; H-10 to MeOC-9, 11% H-12, 13 to H-11, 4%; H-12, 13 to H-3, 6%; H-12, 13 to H-2, 2%.

Preparation of secosarcocapnine (13). A mixt. of sarcocapnine (4) (0.100 g, 0.29 mmol), MeI (4 ml) and MeOH (5 ml) was stirred at room temp. for 36 hr. After removal of solvent, sarcocapnine methiodide was dissolved in EtOH (5 ml) and EtONa (500 mg Na in 10 ml EtOH) was added. The reaction mixt. was refluxed for 4 hr. Solvent was removed, the residue dil. with H₂O (20 ml) and extracted with CH_2Cl_2 (3 \times 15 ml). Prep. TLC purification gave 13 in 70% yield, which was identical (R_f , 1H NMR, MS) to the natural product.

Norsecosarcocapnine (14). Amorphous powder. UV λ_{max}^{EtOH} (log ϵ) nm: 222 (3.6), 244 (3.5), 310 (3.6). IR ν_{max}^{film} cm^{-1} : 3400, 3000–2800, 1600, 1480, 1275, 1090. EIMS m/z (rel. int.): 341 $[M]^+$ (5), 298 (22), 165 (2), 152 (2), 149 (3), 139 (2), 44 (100). Molecular formula $C_{20}H_{23}NO_4$, $[M]^+$ (c: 341.1627; HRMS f: 341.1626). Significant 1H NMR NOEDS are: H-2 to H-12, 13, 2%; H-3 to H-12, 13, 5%; H-3 to H-4, 4%; MeOC-6 to H-5, 3%; MeOC-9 to H-10, 4%; H-10 to MeOC-9, 7%.

N-Methylation of norsecosarcocapnine (14). To a soln of 14 (0.010 g, 0.03 mmol) in MeOH (2 ml) was added 1 ml of HCHO (26%) and the mixt. heated to 45–50° for 30 min. After cooling, excess $NaBH_4$ was added and the reaction mixt. stirred at room temp. for 1.5 hr. Solvent was removed, the residue washed with H₂O (3 \times 5 ml) and extracted with CH_2Cl_2 (3 \times 10 ml). The dried extracts (Na_2SO_4) were concd and purified by prep. TLC, giving secosarcocapnine (13).

N-Methylsecoglaucine (15). Amorphous powder. UV λ_{max}^{MeOH} (log ϵ) nm: 269 (4.41), 2.85 (3.90) (sh), 322 (3.67), 349 (2.56) and 367 (2.54). IR ν_{max}^{KBr} cm^{-1} : 3000–2750, 1585, 1515, 1470, 1265, 1240, 1110. EIMS m/z (rel. int.): 369 $[M]^+$ (66), 311 (17), 279 (13), 149 (20), 58 $[CH_2=NMe_2]^+$ (100). Molecular formula $C_{22}H_{27}NO_4$, $[M]^+$ (c: 369.1940; HRMS f: 369.1942). Significant 1H NMR NOEDS are: H-2 to MeOC-3, 10%; H- α to H-2, 5%; H- α to NMe, 3%; H- α to H-10, 9%; H-10 to H- α , 7%; H- β to NMe, 5%; H- β to H-10, 3%; MeOC-4 to H-5, 2%; MeOC-6 to H-5, 7%; H-8 to MeOC-7, 11%; H-8 to H-9, 13%.

(+)-O-Methylpallidine N-oxide (16). Amorphous compound. $[\alpha]_D^{20} + 20^\circ$ ($CHCl_3$; c 2.1). UV λ_{max} (log ϵ) nm: 240 (4.47), 2.86 (3.99). IR ν_{max}^{film} cm^{-1} : 1670, 1640, 1620. ^{13}C NMR (62.83 MHz, $CDCl_3$): δ 179.9 (s, CO), 155.3, 152.0, 149.2, 149.1 (C-6, C-2, C-3, C-14), 130.4 (C-12), 126.9 (C-11), 123.8 (C-8), 116.7 (C-5), 116.5 (C-4), 109.1 (C-1), 76.1 (C-9), 60.1 (C-16), 57.7, 56.3, 56.0 (3 \times OMe), 55.2 (NMe), 40.4, 36.7 (C-13, C-15), 35.6 (C-10). EIMS m/z (rel. int.): 357 $[M]^+$ (10), 341 $[M-16]^+$ (13), 298 (40), 284 (100). Molecular formula $C_{20}H_{23}NO_5$, $[M]^+$ (c: 357.1576; HRMS f: 357.1587).

(+)-Ribasidine (17). Needles, mp 230° ($CHCl_3$). $[\alpha]_D^{20} + 120^\circ$ (EtOH; c 0.04). UV λ_{max}^{EtOH} (log ϵ) nm: 211 (4.48), 235 (3.98) (sh), 291

(3.98); $\lambda_{max}^{EtOH-HCl}$ (log ϵ) nm: 242 (3.93). IR ν_{max}^{KBr} cm^{-1} : 3580, 3050–2860, 1485, 1255, 1030. ^{13}C NMR (20 MHz, $CDCl_3$ – CD_3OD): δ 149.69 (s), 147.17 (s), 146.86 (s), 143.89 (s), 137.77 (s), 132.02 (s), 129.48 (s), 123.60 (d), 113.75 (s), 108.86 (d), 107.48 (d), 105.25 (d), 101.63 (t), 101.44 (t), 95.98 (s), 89.24 (d), 71.64 (d), 66.88 (d), 36.04 (t), 35.04 (q, NMe). EIMS m/z (rel. int.): 367 $[M]^+$ (31), 366 (11), 204 (5), 192 (100), 188 (38), 176 (34), 163 (11), 149 (7), 146 (6). Molecular formula $C_{20}H_{17}NO_6$, $[M]^+$ (c: 367.1056; HRMS f: 367.1056).

Acknowledgements—We thank the CAICYT (Spain) for financial support and the Midwest Center for Mass Spectrometry (Department of Chemistry, University of Nebraska U.S.A.) for performing high resolution MS. E.T. thanks the Ministerio de Educación y Ciencia (Spain) for an FPI grant.

REFERENCES

1. Castedo, L. and Suau, R. (1986) *The Cularine Alkaloids in The Alkaloids*, Vol. 29 (Manske, R.H.F., ed.). Academic Press, New York.
2. Polunin, O. and Smythies, B. E. (1981) *Guía de Campo de Las Flores de España, Portugal y Sudoeste de Francia* Omega, Barcelona.
3. Vidal, M. C. (1984) Doctoral Thesis. Santiago de Compostela, Spain.
4. Clark, G. R., Manske, R. H. F., Palenik, G. J., Rodrigo, R., McLean, D. B., Bacznyskyj, L., Gracey, D. E. F. and Saunders, J. K. (1970) *J. Am. Chem. Soc.* **92**, 4998.
5. Campello, M. J., Castedo, L., Saá, J. M., Suau, R. and Vidal, M. C. (1982) *Tetrahedron Letters* **23**, 239.
6. Campello, M. J., Castedo, L., Domínguez, D., Rodríguez de Lera, A., Saá, J. M., Suau, R., Tojo, E. and Vidal, M. C. (1984) *Tetrahedron Letters* **25**, 5933.
7. Boente, J. M., Castedo, L., Cuadros, R., Rodríguez de Lera, A., Saá, J. M., Suau, R. and Vidal, M. C. (1983) *Tetrahedron Letters* **24**, 2303.
8. Boente, J. M., Castedo, L., Rodríguez de Lera, A., Saá, J. M., Suau, R. and Vidal, M. C. (1984) *Tetrahedron Letters* **25**, 1829.
9. Boente, J. M., Castedo, L., Rodríguez de Lera, A., Saá, J. M., Suau, R. and Vidal, M. C. (1983) *Tetrahedron Letters* **24**, 2295.
10. Boente, J. M., Campello, M. J., Castedo, L., Domínguez, D., Saá, J. M., Suau, R. and Vidal, M. C. (1983) *Tetrahedron Letters* **24**, 4481.
11. Gözler, B. and Shamma, M. (1984) *J. Nat. Prod.* **47**, 753.
12. Guinaudeau, H., Leboeuf, M. and Cavé, A. (1975) *J. Nat. Prod.* **3**, 275.
13. Krane, B. D., Fagbule, M. O., Shamma, M. and Gözler, B. (1984) *J. Nat. Prod.* **47**, 1.
14. Anet, F. A. L. and Brown, M. A. (1967) *Tetrahedron Letters* **48**, 4881.
15. Boente, J. M., Castedo, L., Domínguez, D., Fariña, A., Rodríguez de Lera, A. and Villaverde, M. C. (1984) *Tetrahedron Letters* **25**, 889.
16. Brochmann-Hanssen, E. and Nielsen, B. (1966) *Tetrahedron Letters* **20**, 2261.
17. Boente, J. M., Castedo, L., Cuadros, R., Saá, J. M., Suau, R., Perales, A., Martínez-Ripoll, M. and Fayos, J. (1983) *Tetrahedron Letters* **24**, 2029.
18. Veechietti, V., Casagrande, C., Ferrari, G., Danieli, B. and Palmisano, G. (1980) *J. Chem. Soc. Perkin Trans I* 578.
19. Roblot, F., Hocquemiller, R., Cavé, A. and Moretti, C. (1983) *J. Nat. Prod.* **46**, 862.

20. Castedo, L., Domínguez, D., López, S., Rodríguez de Lera, A., Tojo, E. and Villaverde, C. (1987) *Heterocycles* **26**, 29.
21. Rodríguez de Lera, A., Saá, J. M., Suau, R. and Castedo, L. (1987) *J. Heterocycl. Chem.* **24**, 95.
22. Castedo, L., Domínguez, D., Lera, A. R. and Tojo, E. (1984) *Tetrahedron Letters* **25**, 4573.
23. Rodríguez de Lera, A., Suau, R. and Castedo, L. (1987) *J. Heterocycl. Chem.* **24**, 313.
24. Castedo, L., Domínguez, D., López, S., Tojo, E. and Villaverde, C. (1987) *Heterocycles* **26**, 591.
25. Tojo, E., Domínguez, D. and Castedo, L. (1988) *Heterocycles* **27**, 2367.
26. Cannon, J. G., Khonje, P. R. and Long, J. P. (1975) *J. Med. Chem.* **18**, 110.
27. Stuart, K. L. (1971) *Chem. Rev.* **71**, 47.
28. Theuns, H. G., Janssen, R. H. A. M., Seykens, D. and Salemink, C. A. (1985) *Phytochemistry* **24**, 581.
29. Theuns, H. G., Janssen, R. H. A. M., Biessels, H. W. A. and Salemink, C. A. (1984) *Org. Magn. Reson.* **22**, 793.
30. Tojo, E., Domínguez, D. and Castedo, L. (1989) *J. Nat. Prod.* **52**, 415.